- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ustekinumab effective long term treatment for active Psoriatic Arthritis: SUSTAIN Study data
Psoriatic arthritis (PsA) is a chronic, progressive disease that places a significant burden on patients and healthcare systems. The SUSTAIN study collected real world evidence on long-term effectiveness, impact on quality of life, and safety of ustekinumab treatment for PsA.
SUSTAIN (Sustainability of effectiveness, safety and patient-reported outcomes for UStekinumab in the Treatment of Active psoriatic arthritis IN a real-life cohort) was a prospective, non-interventional study conducted in Germany. Patients with active PsA received ustekinumab for 160 weeks in routine clinical care, with assessments at baseline, week 4, and every 12 weeks thereafter. This analysis focuses on patients who remained in SUSTAIN until week 160.
Key findings of the study were:
• Of 337 patients enrolled, 129 were documented at week 160, of which 123 (95.3%) had received previous PsA medication, including biologics.
• The 45 mg dose was given to 89 (69.5%) patients, while the 90 mg dose was given to 39 (30.5%) patients; data were missing for 1 patient.
• The mean weight-adjusted ustekinumab dose was 0.7 (SD 0.2) mg/kg body weight.
• Concurrent MTX was taken by 69 (53.5%) patients, while an alternative DMARD was taken by 9 (7.0%) patients
• Decreases from baseline to week 4 were observed for tender joint count (TJC, 8.0 to 5.8) and swollen joint count (SJC, 4.5 to 3.1); these decreases continued to week 28 and were maintained to week 160 (1.0 and 0.4, respectively).
• Skin assessments in patients with PsA and psoriasis revealed improvement at week 4, which continued to week 2 with a sustained effect until week 160.
• Similar patterns of response were observed for patient assessed pain, sleep quality, and health scores.
• Improvements in TJC, SJC, Psoriasis Area and Severity Index, and affected body surface area were observed irrespective of the number of prior biologic therapies used.
• Minimal disease activity was achieved by 36 (31.9%) patients at week 28, and by 38 (33.6%) at week 52.
• Ustekinumab-related adverse events (AEs) and serious AEs were reported in 61 (47.3%) and 4 (3.1%) patients, respectively.
• At week 160, 100% of patients assessed ustekinumab tolerability as good or very good.
The authors concluded that – "This analysis of the SUSTAIN study demonstrates that, in routine clinical practice, ustekinumab can provide rapid and sustained (long term) treatment efficacy for up to 160 weeks (3 years), as well as high tolerability, in patients with active PsA who respond to ustekinumab treatment. Of note, ustekinumab was efficacious irrespective of prior biologic use. As the primary aim of any physician treating PsA is to prescribe a well-tolerated therapy, with fast onset and sustained efficacy that also improves QoL, we propose that ustekinumab offers a valuable therapeutic option."
Further reading:
Ustekinumab Is Rapid-Acting and Is an Effective Long Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non interventional SUSTAIN Study
Jorg Wendler, Nils Damann et al
Rheumatology Therapy (2022) 9:1435–1450
https://doi.org/10.1007/s40744-022-00484-3
MBBS, Dip. Ortho, DNB ortho, MNAMS
Dr Supreeth D R (MBBS, Dip. Ortho, DNB ortho, MNAMS) is a practicing orthopedician with interest in medical research and publishing articles. He completed MBBS from mysore medical college, dip ortho from Trivandrum medical college and sec. DNB from Manipal Hospital, Bengaluru. He has expirence of 7years in the field of orthopedics. He has presented scientific papers & posters in various state, national and international conferences. His interest in writing articles lead the way to join medical dialogues. He can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751